Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

被引：44

作者：

Stahl, Stephen M. ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,10
,11
,12
,13
,14
,15
,16
,17
,18
,19
,20
,21
,22
,23
,24
,25
,26
,27
,28
,29
,30
,31
,32
,33
,34
,35
,36
,37
,38
,39
,40
,41
,42
,43
,44
,45
,46
,47
,48
,49
,50
,51
,52
,53
,54
,55
,56
,57
,58
]}

机构：

[1] Univ Calif San Diego, Psychiat, La Jolla, CA 92093 USA

[2] Univ Cambridge, Cambridge, England

[3] Calif Dept State Hosp, Psychopharmacol, Sacramento, CA 95814 USA

[4] Acadia, San Diego, CA USA

[5] Adamas, Emeryville, CA USA

[6] Alkermes, Dublin, Ireland

[7] Allergan, Dublin, Ireland

[8] Arbor Pharmaceutcials, Atlanta, GA USA

[9] AstraZeneca, Cambridge, England

[10] Avanir, Aliso Viejo, CA USA

[11] Axovant, Hamilton, Bermuda

[12] Axsome, New York, NY USA

[13] Biogen, Cambridge, MA USA

[14] Biomarin, Novato, CA USA

[15] Biopharma, Cary, NC USA

[16] Celgene, Summit, NJ USA

[17] Concert, Bristol, Avon, England

[18] ClearView, Princeton, NJ USA

[19] DepoMed, Newark, CA USA

[20] Dey, Wayne, NJ USA

[21] EnVivo, Watertown, MA USA

[22] EMD Serono, Rockland, MA USA

[23] Ferring, St Prex, Switzerland

[24] Forest, New York, NY USA

[25] Forum, Watertown, MA USA

[26] Genomind, King Of Prussia, PA USA

[27] Innovat Sci Solut, Morristown, NJ USA

[28] Intra Cellular Therapies, New York, NY USA

[29] Janssen, Beerse, Belgium

[30] Jazz, Dublin, Ireland

[31] Lilly, Indianapolis, IN USA

[32] Lundbeck, Copenhagen, Denmark

[33] Merck, Kenilworth, NJ USA

[34] Neos, Grand Prairie, TX USA

[35] Novartis, Basel, Switzerland

[36] Noveida, New York, NY USA

[37] Orexigen, La Jolla, CA USA

[38] Otsuka, San Francisco, CA USA

[39] PamLabs, Carlsbad, CA USA

[40] Perrigo, Dublin, Ireland

[41] Pfizer, New York, NY USA

[42] Pierre Fabre, Paris, France

[43] Reviva, Paris, France

[44] Servier, Neuilly Sur Seine, France

[45] Shire, Lexington, MA USA

[46] Sprout, Chicago, IL USA

[47] Sunovion, London, England

[48] Taisho, Toshima, Tokyo, Japan

[49] Taliaz, Tel Aviv, Israel

[50] Teva, Petah Tiqwa, Israel

来源：

CNS SPECTRUMS | 2019年 / 24卷 / 05期

关键词：

MAJOR DEPRESSIVE DISORDER; ANTIDEPRESSANT MEDICATIONS; AMPA RECEPTORS; PATHOPHYSIOLOGY; LEVOMETHORPHAN; KETAMINE;

D O I：

10.1017/S1092852919001470

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinforced the need for agents with rapid onset with alternate mechanisms of action. Dextromethorphan/bupropion, an investigational medicine currently in development, is one such candidate.

引用

页码：461 / 466

页数：6

共 50 条

[1] Dextromethorphan/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity (vol 24, pg 461, 2019)
Stahl, Stephen M.
CNS SPECTRUMS, 2020, 25 (06) : 803 - 803
[2] Antihyperalgesic effect of the N-methyl-D-aspartate receptor antagonist dextromethorphan in the oral surgery model
Gordon, SM
Dubner, R
Dionne, RA
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (02): : 139 - 146
[3] Effects of the N-methyl-D-Aspartate receptor antagonist dextromethorphan on vibrotactile adaptation
Stephen E Folger
Vinay Tannan
Zheng Zhang
Jameson K Holden
Mark Tommerdahl
BMC Neuroscience, 9
[4] Effects of the N-methyl-D-Aspartate receptor antagonist dextromethorphan on vibrotactile adaptation
Folger, Stephen E.
Tannan, Vinay
Zhang, Zheng
Holden, Jameson K.
Tommerdahl, Mark
BMC NEUROSCIENCE, 2008, 9 (1)
[5] Dextromethorphan:: A review of N-methyl-D-aspartate receptor antagonist in the management of pain
Siu, Anita
Drachtman, Richard
CNS DRUG REVIEWS, 2007, 13 (01): : 96 - 106
[6] ATTENUATION OF HIPPOCAMPAL INHIBITION BY A NMDA (N-METHYL-D-ASPARTATE) RECEPTOR ANTAGONIST
CAPEK, R
ESPLIN, B
NEUROSCIENCE LETTERS, 1991, 129 (01) : 145 - 148
[7] N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST AND ASD: A SYSTEMATIC REVIEW
Gupta, Nihit
Gupta, Mayank
Emereonye, Kelechi N.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S296 - S296
[8] N-METHYL-D-ASPARTATE (NMDA) ANTAGONIST AND PARKINSONS-DISEASE - A PILOT-STUDY WITH DEXTROMETHORPHAN
MONTASTRUC, JL
FABRE, N
RASCOL, O
SENARD, JM
BLIN, O
MOVEMENT DISORDERS, 1994, 9 (02) : 242 - 243
[9] Synthesis and N-Methyl-D-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, Patrick J.
Moaddel, Ruin
Zanos, Panos
Moore, Curtis E.
Gould, Todd
Zarate, Carlos A., Jr.
Thomas, Craig J.
ORGANIC LETTERS, 2017, 19 (17) : 4572 - 4575
[10] Treatment with the N-methyl-D-aspartate receptor antagonist dextromethorphan in severe bacterial meningitis: preliminary results
B. Schmitt
G. Wohlrab
M. Steinlin
S. Fanconi
D. Nadal
E. Boltshauser
European Journal of Pediatrics, 1998, 157 : 863 - 865

← 1 2 3 4 5 →